Rhythm Pharmaceuticals Reports First Quarter 2024 Financial Results and Business Update
Rhythm Pharmaceuticals, Inc. (RYTM)
Last rhythm pharmaceuticals, inc. earnings: 3/8 08:12 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.rhythmtx.com
Company Research
Source: GlobeNewswire
-- First quarter 2024 net revenue from global sales of IMCIVREE® (setmelanotide) of $26.0 million -- -- On track to submit sNDA to the FDA to treat pediatric patients between 2 and younger than 6 years old in approved indications in second quarter of 2024 -- -- Phase 3 trial evaluating setmelanotide in hypothalamic obesity remains on track for topline data readout in 1H 2025; dosing of first patients in Japan anticipated in 2Q 2024 -- -- Secured $150 million in convertible preferred stock financing, funding planned operations into 2026 -- -- Management to host conference call today at 8:00 a.m. ET -- BOSTON, May 07, 2024 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients and their families living with rare neuroendocrine diseases, today reported financial results and provided a business update for the first quarter ended March 31, 2024. “We continue to
Show less
Read more
Impact Snapshot
Event Time:
RYTM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RYTM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RYTM alerts
High impacting Rhythm Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RYTM
News
- Rhythm Pharmaceuticals Announces New Employment Inducement Grants [Yahoo! Finance]Yahoo! Finance
- Rhythm Pharmaceuticals Announces New Employment Inducement GrantsGlobeNewswire
- Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) had its price target lowered by analysts at Canaccord Genuity Group Inc. from $80.00 to $79.00. They now have a "buy" rating on the stock.MarketBeat
- Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) Q1 2024 Earnings Call Transcript [Yahoo! Finance]Yahoo! Finance
- Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM) was downgraded by analysts at Bank of America Co. from a "buy" rating to a "neutral" rating. They now have a $42.00 price target on the stock, down previously from $49.00.MarketBeat
RYTM
Earnings
- 5/7/24 - Miss
RYTM
Sec Filings
- 5/13/24 - Form 4
- 5/9/24 - Form 144
- 5/7/24 - Form 10-Q
- RYTM's page on the SEC website